Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696626 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
A Phase 3 study of Metastatic Breast Cancer, sponsored by Sermonix Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT05696626 is a Phase 3 study of Metastatic Breast Cancer that is actively recruiting participants, run by Sermonix Pharmaceuticals. The registered enrollment target is 500 participants, above the 201-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (149% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05696626, a Phase 3 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Sermonix Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Conditions Studied
Interventions
- DRUG Lasofoxifene in combination with abemaciclib
- DRUG Fulvestrant in combination with abemaciclib
Study Locations (20)
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Miami Cancer Institute - Miami
- Miami Cancer Institute Plantation - Plantation
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
- University of Arizona - Cancer Center - Tucson
Minnesota
- Allina Health System DBA Virginia Piper Cancer Institute - Minneapolis
- Mayo Clinic - Rochester - Rochester
Missouri
- Saint Luke's Cancer Institute - Kansas City
- Washington University School of Medicine - St Louis
Nevada
- Renown Regional Medical Centre - Reno
- Cancer Care Specialists - Reno
California
- Providence Medical Foundation - Santa Rosa, CA - Santa Rosa
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05696626
The ClinicalTrials.gov registry entry for NCT05696626 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 201-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (149% higher). The listed sponsor is Sermonix Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Lasofoxifene in combination with abemaciclib is the first listed.
NCT05696626 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT05696626 about?
NCT05696626 is a clinical study titled "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation". The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatm...
What is the current status of trial NCT05696626?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-10-31. Estimated completion is 2028-04.
What conditions does trial NCT05696626 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05696626?
The interventions under investigation include: Lasofoxifene in combination with abemaciclib (DRUG), Fulvestrant in combination with abemaciclib (DRUG).
Who is sponsoring clinical trial NCT05696626?
This trial is sponsored by Sermonix Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696626 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RECRUITING · Phase 3
-
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RECRUITING · Phase 3
-
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 3
-
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
RECRUITING · Phase 3
-
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.